Downregulation of serum miR-17 and miR-106b levels in gastric cancer and benign gastric diseases

HFCAS OpenIR

	Downregulation of serum miR-17 and miR-106b levels in gastric cancer and benign gastric diseases
其他题名	Downregulation of serum miR-17 and miR-106b levels in gastric cancer and benign gastric diseases
	2014
发表期刊	CHINESE JOURNAL OF CANCER RESEARCH
ISSN	1000-9604
摘要	Altered microRNA (miRNA) associated with gastric cancer (GC) development and miR-17 and miR-106b were differentially expressed in GC tissues. This study detected serum levels of miR-17 and miR-106b expression in GC, benign gastric disease (BGD) and healthy controls to assess them as tumor markers for GC. Serum samples from 40 GC, 32 BGD (10 gastric ulcer, 14 gastric polyps, and 8 gastric ulcer with polyps) and 36 healthy individuals were subjected to quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of miR-17 and miR-106b expression. The data showed that the serum levels of miR-17 and iniR-106b were significantly reduced in healthy individuals and BGD patients compared to GC patients. There was a significant association of miR-17 and miR-106b expression with age, but not with other clinicopathological features, such as gender, tumor differentiation, stage and lymphatic metastasis. Further analysis showed that, in discriminating GC patients from healthy controls, miR-17 could yield a receiver-operating characteristic (ROC) area under the curve (AUC) of 0.879 with 80.6% sensitivity and 87.5% specificity and miR-106b could yield an AUC of 0.856 with 75.0% sensitivity and 92.5% specificity. The combined AUC of miR-17 and miR-106b was 0.913 with 83.3% sensitivity and 87.5% specificity. Collectively, these data suggest that detection of serum miR-17 and miR-106b levels should be further evaluated as novel non-invasive biomarkers in early GC detection and surveillance of disease progression.
其他摘要	Altered microRNA (miRNA) associated with gastric cancer (GC) development and miR-17 and miR-106b were differentially expressed in GC tissues. This study detected serum levels of miR-17 and miR-106b expression in GC, benign gastric disease (BGD) and healthy controls to assess them as tumor markers for GC. Serum samples from 40 GC, 32 BGD (10 gastric ulcer, 14 gastric polyps, and 8 gastric ulcer with polyps) and 36 healthy individuals were subjected to quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of miR-17 and miR-106b expression. The data showed that the serum levels of miR-17 and miR-106b were significantly reduced in healthy individuals and BGD patients compared to GC patients. There was a significant association of miR-17 and miR-106b expression with age, but not with other clinicopathological features, such as gender, tumor differentiation, stage and lymphatic metastasis. Further analysis showed that, in discriminating GC patients from healthy controls, miR-17 could yield a receiver-operating characteristic (ROC) area under the curve (AUC) of 0.879 with 80.6% sensitivity and 87.5% specificity and miR-106b could yield an AUC of 0.856 with 75.0% sensitivity and 92.5% specificity. The combined AUC of miR-17 and miR-106b was 0.913 with 83.3% sensitivity and 87.5% specificity. Collectively, these data suggest that detection of serum miR-17 and miR-106b levels should be further evaluated as novel non-invasive biomarkers in early GC detection and surveillance of disease progression.
关键词	CIRCULATING MICRORNAS miR-17 miR-106b gastric cancer (GC) benign gastric disease (BGD) biomarker
收录类别	CSCD
语种	英语
资助项目	[National Natural Science Foundation of China] ; [Ph.D. Programs Foundation of Ministry of Education of China] ; [Post-doctoral Foundation of Central South University] ; [China Postdoctoral Science Foundation] ; [Key Program for International Cooperation Projects of Hunan Province] ; [Natural Science Foundation of Hunan Province] ; [Technology Project of Hunan Province] ; [Research foundation of Health Department of Hunan Province] ; [125 Talent Project of the Third Xiangya Hospital of Central South University]
CSCD记录号	CSCD:5322021
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/57785
专题	中国科学院合肥物质科学研究院
推荐引用方式 GB/T 7714	. Downregulation of serum miR-17 and miR-106b levels in gastric cancer and benign gastric diseases[J]. CHINESE JOURNAL OF CANCER RESEARCH,2014,26.
APA	(2014).Downregulation of serum miR-17 and miR-106b levels in gastric cancer and benign gastric diseases.CHINESE JOURNAL OF CANCER RESEARCH,26.
MLA	"Downregulation of serum miR-17 and miR-106b levels in gastric cancer and benign gastric diseases".CHINESE JOURNAL OF CANCER RESEARCH 26(2014).